Humacyte Surges 77% on FDA Approval for Symvess Vascular Repair Product
Humacyte (NASDAQ:HUMA) shares climbed ~77% in the premarket on Friday after the bioengineered tissue maker announced the FDA approval of Symvess, an off-the-shelf, implantable vascular conduit indicated for arterial injury.
According to the FDA labeling, Symvess will be available for adults with arterial injury in extremities. It will be indicated when an autologous vein graft is not feasible when there is a risk of near-term limb loss, and in other cases for urgent revascularization.
“SYMVESS approval in this first indication for arterial injury repair is a milestone for regenerative medicine overall, as well as for Humacyte,” CEO Laura Niklason remarked.
The Durham, North Carolina-based company said it has already recruited and trained sales personnel in preparation for the product’s commercial launch.
HUMA’s marketing application for Symvess is backed by real-world data and results from its V005 pivotal Phase 2/3 clinical study, which met its primary goals in patients with arterial injuries due to traumatic events such as gunshot wounds.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10